# Cantai Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cantai-therapeutics

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Total disclosed funding: $0.7M
- Latest round: Seed (Nov 6, 2023)
- Investors on record: 3

## About

Founded in 2023 and based in Pennsylvania, US, Cantai Therapeutics, Inc., also known as Cantai, operates as a biotechnology company that offers drugs for patients suffering from autoimmune diseases. In November 2023, Cantai Therapeutics, Inc. raised USD 700,000 in seed funding, co-led by new investors Agent Capital, Alloy Therapeutics, Inc., and Tellus BioVentures. The round was part of a larger USD 3 million seed funding.

Cantai develops drug candidates, mainly cytokine-targeting bispecific antibodies, for patients with inflammatory disorders. The firm leverages human antibody discovery technologies to offer therapies for patients suffering from autoimmune diseases.

The company plans to use the funds raised in November 2023 to support the development of its drugs.

## Funding rounds

- Seed, Nov 6, 2023, $0.7M — Agent Capital, Tellus BioVentures, Alloy Therapeutics, Inc.

## Investors

- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Seed
- Tellus BioVentures (https://capitalatlas.ai/funds/tellus-bioventures) — Seed
- Alloy Therapeutics, Inc. — Seed